Objective:
To evaluate the effects of high-dose oral vitamin D on chemotherapy- and radiation-associated skin toxic effects.
Approach:
- Study Design: Retrospective multicenter case series involving 33 patients treated by oncodermatologists at 3 academic medical centers.
- Patient Demographics: Mean age of 60.9 years; 58% female; 85% with toxic erythema of chemotherapy (TEC) and 15% with acute radiation dermatitis (ARD).
- Intervention: Patients received 1 or 2 oral doses of 100,000 IU of cholecalciferol or ergocalciferol.
- Outcomes Measured: Primary outcomes included time to symptom relief and clinician-assessed improvement in erythema; secondary outcomes included serum calcium changes and continuity of anticancer therapy.
Key Findings:
- 87% of patients reported subjective symptom relief within 10 days.
- 77% had clinician-assessed improvement in erythema.
- Median time to improvement was 5 days overall and 3 days for inpatients.
- Mean erythema scores decreased significantly from 4.36 at baseline to 2.21 by day 10.
- 73% of patients continued anticancer therapy without interruption.
Interpretation:
The uncontrolled design and concomitant therapies limit attributing improvements solely to vitamin D.
Limitations:
- Retrospective design without a placebo or control group.
- Variable follow-up and potential selection bias.
- Incomplete laboratory data and use of a nonvalidated erythema scale.
- Limited number of patients with ARD.
Conclusion:
Further prospective controlled trials are needed to establish the efficacy, safety, and optimal dosing of high-dose vitamin D for treating skin toxic effects from cancer therapies.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
